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specifically, this disclosure relates to methods for treating
degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
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COMPOSITIONS AND METHODS FOR
TREATING RETINAL DEGRADATION

prising administering an effective amount of a composition to
a subject in need thereof, wherein the composition comprises
a reverse transcriptase inhibitor, such as a nucleoside reverse
transcriptase inhibitor (NRTI), selected from: (i) a compound
having the structure of

RELATED APPLICATIONS
5

This application claims priority from U.S. Provisional
Application Ser. No. 61/861,290, filed Aug. 1, 2013, and from
U.S. Provisional Application Ser. No. 61/987,612, filed May
2, 2014, the entire disclosures of which are incorporated
herein by this reference.
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TECHNICAL FIELD
The presently-disclosed subject matter relates to compositions for treating retinal damage and/or degradation. More
specifically, this disclosure relates to methods for treating
degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside reverse transcriptase inhibitor (NRTI).

15

I

H3C

20

0:9

or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of

BACKGROUND
Geographic atrophy, an advanced form of age-related
macular degeneration that causes blindness in millions of
people worldwide and for which there is no approved treatment, results from death of retinal pigmented epithelium
(RPE) cells. For example, expression ofDICER, an enzyme
involvedinmicroRNA (miRNA) biogenesis, is reduced in the
RPE of human eyes with geographic atrophy, and that conditional ablation ofDicerl induces RPE degeneration in mice.
Surprisingly, ablation of seven other enzymes responsible for
miRNA biogenesis or function does not induce such pathology. Instead, knockdown of DICERl leads to accumulation
of Alu repeat RNA in human RPE cells and of Bl and B2
(Alu-like elements) repeat RNAs in the RPE of mice. Alu
RNA is dramatically increased in the RPE ofhuman eyes with
geographic atrophy, and introduction of this pathological
RNA induces death of human RPE cells and RPE degeneration in mice.
Age-related macular degeneration (AMD), which is as
prevalent as cancer in industrialized countries, is a leading
cause of blindness worldwide. In contrast to the neovascular
form ofAMD, for which many approved treatments exist, the
far more common atrophic form of AMD remains poorly
understood and without effective clinical intervention. Ext ensive atrophy of the retinal pigment epithelium leads to severe
vision loss and is termed geographic atrophy.
Hence, there remains a need for compositions and methods
for treating retinal degradation, and particularly RPE degradation.
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BRIEF SUMMARY
This summary describes several embodiments of the presently-disclosed subject matter, and in many cases lists variations and permutations of these embodiments. This s=ary
is merely exemplary of the numerous and varied embodiments. Mention of one or more representative features of a
given embodiment is likewise exemplary. Such an embodiment can typically exist with or without the feature(s) mentioned; likewise, those features can be applied to other
embodiments of the presently-disclosed subject matter,
whether listed in this summary or not. To avoid excessive
repetition, this summary does not list or suggest all possible
combinations of features.
The present disclosure provides, in certain embodiments, a
method for treating retinal damage and/or degradation, com-
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CH3

or a pharmaceutically acceptable salt thereof; (iii) stavudine
(d4T); (iv) lamivudine (3TC); (v) cordycepin; (vi) azidothymidine (AZT); (vii) abacavir (ABC); and/or (viii) a combination thereof.
Moreover, the methods of the present disclosure may further comprise the steps of (i) inhibiting inflammasome activation by Alu RNA; (ii) reducing ATP-induced permeability
of a cell; (iii) reducing an amount of mitochondrial reactive
oxygen species in a cell; and/or (iv) inhibiting activation of at
least one inflammasome in a subject's eye. Additionally, the
cell(s) of the methods of the present disclosure may be chosen, for example, from a retinal pigmented epithelium cell, a
retinal photoreceptor cell, a choroidal cell, and a combination
thereof. And an inflammasome of the present disclosure may
be, for example, an NLRP3 inflammasome, an IL-l beta
inflammasome, or a combination thereof.
Furthermore, in some embodiments, the present disclosure
provides a compound having the structure:

US 9,326,983 B2
3
or a pharmaceutically acceptable salt thereof;
or a compound having the structure

4

FIG. 6 is a Western blot showing that Alu RNA causes
Caspase-1 maturation in primary human RPE cells at 24
hours after Alu administration (top, middle lane, lower band),
which is blocked with co-treatment with 3TC (20-100 uM;
5 rightmost lane), wherein the lowermost band is the loading
control, vinculin.
FIG. 7 is a Western blot showing that Alu RNA causes
Caspase-1 maturation in primary human RPE cells at 24
hours after Alu administration (top, middle lane, lower band),
10
which is blocked with co-treatment with azidothymidine
(AZT), cordycepin, and abacavir (ABC) (50-100 uM; lanes
3-8 from left). The loading control vinculin is shown on the
bottom.
FIG. 8 provides a gel showing that primary human RPE
15
cells treated with LPS/ATP, a classic inflammasome activator,
exhibit increased Casp-1 activation, and phosphorylation of
IRAK4, which is also a marker of inflammasome signaling
via the cell surface receptor adaptor protein MyD88. More20 over, as shown in FIG. 8, d4T (25/100 uM) blocks Casp-1
or a pharmaceutically acceptable sale thereof.
activation and IRAK4 phosphorylation induced by LPS/ATP.
The present disclosure also provides a pharmaceutical
Vinculin was used as the loading control in the gel of FIG. 8.
composition comprising at least one of the compounds proAdditionally, as shown, LPS and ATP activate the NLRP3
vided in the present disclosure, together with a pharmaceutiinflammasome only in combination.
cally acceptable carrier. And further embodiments of the 25
FIG. 9 provides the results of Western blotting, wherein
present disclosure include a method for synthesizing at least
d4T, 3TC, and cordycepin (at 100 uM), all di-deoxy nucleoone compound provided in the present disclosure.
side reverse transcriptase inhibitors, are shown to inhibit
Caspase-1 activation (active p20 band, top) and IL-18 matuBRIEF DESCRIPTION OF THE DRAWINGS
ration (bottom) induced by LPS/ATP. To produce FIG. 9, cell
30 culture supernatants were collected after (i) no treatment, (ii)
FIG. 1 displays a top row of ocular fundus photographs of
LPS treatment, or (iii) LPS/ATP treatment of mouse bone
mice receiving control PBS, or Alu RNA treatment, with or
marrow-derived macrophages and run on Western blotting
without increasing amounts of d4 T (left to right); and RPE flat
probing with antibodies for Caspase-1 and IL-18.
FIG. 10 provides the result of a Western blot showing that
mounts, stained for intercellular junctions (Z0-1) in red that
are disrupted upon Alu RNA administration but that are 35 d4T (1 00, 250 uM) inhibits IL-l beta maturation (top, 18 and
restored to healthy RPE morphology/intercellular junctions
22 kDa forms) and Caspase-1 activation (active p20 band,
at highest dose of d4 T.
bottom) induced by nigericin. To produce FIG. 10, cell culture supernatants were collected after (i) no treatment, (ii)
FIG. 2 provides a bar graph showing that human (HeLa)
LPS treatment, or (iii) LPS/nigericin treatment of mouse bone
cells treated with an enforced expression plasmid for Alu
RNA (pAluA) for denoted amounts of time exhibited pro- 40 marrow-derived macrophages and run on Western blotting
foundly reduced viability compared to a null plasmid
probing with antibodies for IL-l beta and Caspase-1.
FIG. 11 shows a bar graph illustrating that d4T does not
(pUC19), as monitored by MTS proliferation assay and that
inhibit IL-l beta secretion from PMA-differentiated THP-1
d4T co-administration prevented cell death induced by Alu
overexpression.
monocytes induced by monosodium urate (MSU). FIG. 11
FIG. 3 shows the results of Northern blotting using an 45 was created after human THP-1 monocytes were differentiated into macrophages with PMA, and, as shown in FIG. 11,
Alu-specific probe. As presented in FIG. 3, primary human
RPE cells treated with antisense oligonucleotides targeting
treatment with MSU, a known inflammasome activator,
increased IL-l beta secretion compared to non-treated cells,
DICERl (Dcr as) (lane 3 (third lane from left)) show
increasedAlu RNA levels in the nuclear compartment comwhereas d4T co-administration at a range of doses (25-1000
pared to control antisense oligonucleotides (Ctr as) (lane 1 so uM) did not significantly affect IL-l beta secretion.
(leftmost)), and co-administration of d4 T (lanes 2 and 4) does
FIG. 12 is a bar graph, which shows that d4T and other
not reduce Alu RNA levels. u6 (bottom row) is shown as a
nucleoside reverse transcriptase inhibitors do not inhibit IL-l
beta secretion from PMA-differentiated THP-1 monocytes
loading control for nuclear fraction.
FIG. 4 provides another example of the results ofNorthern
induced by MSU. Human THP-1 monocytes were differentiblotting using an Alu-specific probe. As presented in FIG. 4, 55 ated into macrophages with PMA. Their treatment with MSU
increased IL-l beta secretion compared to non-treated cells,
co-administration of d4 T does not change Alu RNA levels at
as shown in FIG. 12, while co-administration of d4T, 3TC, or
1, 4, or 24 hours after transfection in the nuclear fraction of
human RPE cells transfected with Alu RNA, with or without
cordycepin (all are di -deoxy nucleotide analogs) at a range of
d4T, as detected by Northern blotting using an Alu-specific
doses (25-1 000 uM) did not significantly affect IL-beta secreprobe. u6 (bottom row) is shown as loading control for 60 tion.
FIG. 13 is a graph, which provides that d4T reduces
nuclear fraction in FIG. 4.
NLRP3 priming induced by Alu RNA. Indeed, as shown in
FIG. 5 provides the results of a Western blot showing that
Alu RNA causes Caspase-1 maturation in primary human
FIG. 13, Alu RNA transfection increases NLRP3 mRNA
RPE cells at 24 hours after Alu administration (top, middle
levels in primary human RPE cells at 16 hours, an event
lane, lower band), which is blocked by co-treatment with d4T 65 termed "priming" (Y-axis) compared to mock (transfection
reagent alone). This effect is blunted by co-administration of
(100 uM; rightmost lane). The bottom row is a vinculin loading control.
d4T (1 00 uM) and normalized to ISS RNA control.
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FIG. 14 illustrates, in graph format, that Alu RNA transfection increases IL-l beta mRNA levels in primary human
RPE cells at 24 hours, an event termed "priming", (Y-axis)
compared to mock (transfection reagent alone). This effect is
blunted by co-administration of d4T (100 uM) and normalized to ISS RNA control.
FIG.15 shows that d4T reduces mitochondrial ROS caused
by Alu expression. Indeed, FIG. 15 demonstrates that
enforced expression of Alu (pA!uA) causes increased mitochondrial reactive oxygen species (mtROS), as detected by
MitoSox assay. In order to produce FIG. 15, primary human
RPE cells were incubated with Alu expressing plasmid or
control plasmid (p UC19) with or without d4 T. After 15 hours
cells were co-stained for mtROS (red) and for cell count,
nuclei (blue; Hoechst DNA stain). Cells in the pA!uA group
exhibited greater mtROS staining (red) compared to pUC19
control, an effect that is reduced in pA!uA+d4T treated cells.
FIG.16 provides a graph showing that d4T does not inhibit
ATP release induced by Alu RNA. Moreover, primary human
RPE cells treated with Alu RNA, for the times indicated in
FIG. 16, release ATP. Cell culture supernatant was collected
from mock or Alu RNA treated cells, with or without d4 T, and
ATP was detected using an ATP-dependent luciferase assay.
Notably, d4T did not affect ATP release.
FIG. 17 shows that d4T reduces ATP-induced cell permeability to Yo-Pro! (P2X7 receptor assay). Indeed, d4T dosedependently reduced Yo-Pro entry induced by ATP, determined by an area-scan fluorescent measurement in a 96 well
microplate reader. FIG. 17 provides the results of the fluorescence measurement in relative fluorescence units (RFU,
y-axis).
FIG. 18 illustrates, in graph format, that d4T reduces extracellular potassium levels, which increase after Alu RNA
transfection. Indeed, cell culture potassium levels increase in
primary human RPE cells treated withA!u RNA for 6 hours,
an effect that is reduced by d4 T co-administration. Potassium
levels were determined in cell culture supernatants spectraphotometrically using a potassium-dependent pyruvate
kinase assay.
FIG. 19 shows that d4T blocks bzATP-induced cell permeability to Yo-Pro! (P2X7 receptor assay). To prepare FIG. 19,
d4 T blocked YO-PRO-I iodide entry in HEK293 cells stably
expressing the human P2X7 receptor stimulated with the
P2X7 -selective agonist bzATP. Cells were pre-incubated with
d4T for 30 minutes prior to addition ofbzATPNO-PRO, and
fluorescence (in relative fluorescence units) at 485/515 urn
was measured at t=30 minutes.
FIG. 20 provides a chemical structure of methoxy-d4T
(me-d4T). More specifically, as shown in FIG. 20, a single
substitution of the ribose 5' hydroxyl group of d4T with a
methoxy group (circled) has been designed to prevent d4T
phosphorylation
FIG. 21 is a Western blot of Caspase-1 activation (p20
subunit) in primary human RPE cells transfected with Alu
RNA±me-d4 T.
FIG. 22 shows cells, wherein unmodified d4T, but not
me-d4 T, blocks replication of a GFP-expressing lentivirus in
HeLa cells.
FIG. 23 provides a graph illustrating that unmodified d4T,
but not me-d4T, reduces mtDNA levels (normalized to chromosomal DNA exon-intron junction sequence) in primary
mouse RPE cells as determined by real-time quantitative
PCR. n=4, *p<0.05 by Student's t-test.
FIG. 24 provides flat mounts stained for zonula
occludens-1 (Z0-1; red), bottom row. Degeneration outlined
by blue arrowheads. Representative images ofn=4 (B, C, E)
shown. Scale bars, (C): 200 flill; (E): 20 flill

FIG. 25 provides a schematic overview ofme-d4T syntheSIS.
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FIG. 26 is an HPLC chromatogram ofme-d4T (peak #6)
final product, >97% purity.
FIG. 27 is a lH NMR spectroscopy ofme-d4T final product, wherein the chemical shifts are consistent with the structure ofme-d4T.
FIG. 28 provides the results of liquid chromatography/
mass spectrometry of me-d4T final product, m/z ratio consistent with the structure ofme-d4T.
FIG. 29 provides the methoxy variant of a nucleoside analog. The chemical structure of3TC (2'3' dideoxycytidine) is
shown, wherein the methoxy variation (0-methyl group) of
nucleoside analog is circled.
FIG. 30 provides the methoxy variant of a nucleoside analog. The chemical structure of AZT (3'-azido-2',3'-dideoxythymidine) is shown, wherein the methoxy variation (O-rnethy! group) of nucleoside analog is circled.
FIG. 31 provides the methoxy variant of a nucleoside analog. The chemical structure of ABC (cyclopropylaminopurinylcyclopentene) is shown, wherein the methoxy variation
(0-methyl group) of nucleoside analog is circled.
FIG. 32 shows a cell permeant variant of d4T (IC-d4T),
where "n" group is equal to 11. Derivatives include cell permeant variants of 3TC, AZT, ABC, where the nucleobase
group (circled) may be replaced, in various embodiments, by
3TC, AZT, ABC, or methoxy-variants of d4T, 3TC, AZT,
ABC (FIG. 29-31), or derivatives thereof.
FIG. 33 provides the structure of an exemplary NRTI
according to the present disclosure.
FIG. 34 is a Western blot of Caspase-1 activation (p20
subunit) and IRAK4 phosphorylation in primary human RPE
cells transfected withA!u RNA±d4T.
FIG. 35 is a Western blot ofCaspase-1 activation in human
RPE cells transfected with Alu RNA±NRTis (3TC, AZT,
ABC).
FIG. 36 includes fundus photographs: top row; flat mounts
stained for zonula occludens-1 (Z0-1; red), bottom row. bars,
50 fllll·
FIG. 37 provides fundus photographs: top row; flat mounts
stained for zonula occludens-1 (Z0-1; red), bottom row.
Scale bars, 50 flill.
FIG. 38 illustrates that NRTis block LPS/ATP-induced
inflammasome activation. Specifically, FIG. 38 shows a gel
indicating that d4T blocked Caspase-1.
FIG. 39 also illustrates that NRTis block LPS/ATP-induced inflmasome activation, showing specifically a gel
indicating that d4T blocked IL-l beta.
FIG. 40 presents chromatograms showing that Raji TK+
cells, but not Raji TK- cells, phosphorylate AZT to AZTtriphosphate (AZT-TP) as determined by liquid chromatography-mass spectrometry (LC-MS).
FIG. 41 shows that AZT blocks IL-l beta activation by
LPS/ATP in both Raji TK- and TK+ cells, as determined by
Western blot of celllysates.
FIG. 42 is a bar graph illustrating that d4T does not block
Alu-induced ATP release from primary human RPE cells
(n=4).
FIG. 43 provides a graph of P2X7-mediated YO-PR0-1
dye uptake (fluorescence) induced by bzATP (100 f.LM) in
HEK293 cells stably expressing the human P2X7 receptor
was inhibited by d4T and A438079 (64 f.LM for both drugs).
Fluorescence values are baseline subtracted from cells without bzATP treatment. *bzATP vs. d4T; #bzATP vs.A438079,
p<0.05 by Student-Newman Keuls post-hoc test (n=12).
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FIG. 44 is a Western blot of Caspase-1 activation (p20
subunit) and IRAK4 phosphorylation in primary mouse RPE
cells transfected withAlu RNA±d4T.
FIG. 45 is a Northern blot ofbiotin-UTP-labeledAlu RNAtransfected primary human RPE cells.
FIG. 46 provides LC-MS/MS spectra ofAZT-triphosphate
(AZT-TP).
FIG. 47 provides LC-MS/MS spectra ofAZU-triphosphate
(AZT-TP
FIG. 48 shows the chromatographic separation ofRaji TKcells spiked with AZT-TP with MS spectra (inset) to confirm
identity of designated peaks.
FIG. 49 shows the chromatographic separation ofRaji TKcells spiked withAZU-TP with MS spectra (inset) to confirm
identity of designated peaks.
FIG. 50 is a standard curve of AZT-TP standards (black
circle). As shown, Raji TK+ samples treated withAZT produced AZT-TP (white triangles), whereas AZT-TP was not
detectable in Raji TK- cells treated withAZT.
FIG. 51 is a Western blot of Caspase-1 activation (p20
subunit) in primary human RPE cells transfected with Alu
RNA, with short peptide (Panx1 10), which blocks P2X7 pore
function but not cation flux (vs. scrambled peptide: Scr
Panx1 10).
FIG. 52 is a Western blot of Caspase-1 activation (p20
subunit) in primary human RPE cells transfected with Alu
RNA, with calmidazolium (FIG. 32 provides the chemical
structure ofiC- and EC-d4T used), which blocks P2X7 cation
flux but not pore function.
FIG. 53 is a Western blot of Caspase-1 activation (p20
subunit) in primary human RPE cells transfected with Alu
RNA, with cell permeable (IC), cell-impermeable (EC), or
unmodified (no tag) d4T.
FIG. 54 shows that d4 T prevents pAlu-induced mitochondrial ROS generation in primary human RPE cells. In FIG. 54,
mitochondrial reactive oxygen species (ROS) were visualized with MitoSox (Red) and cell nuclei with Hoechst (Blue).

characteristic( s) or limitation(s) and vice versa, unless otherwise specified or clearly implied to the contrary by the context
in which the reference is made.
All combinations of method or process steps as used herein
can be performed in any order, unless otherwise specified or
clearly implied to the contrary by the context in which the
referenced combination is made.
While the following terms used herein are believed to be
well understood by one of ordinary skill in the art, definitions
are set forth to facilitate explanation of the presently-disclosed subject matter.
Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which the presentlydisclosed subject matter belongs. Although any methods,
devices, and materials similar or equivalent to those described
herein can be used in the practice or testing of the presentlydisclosed subject matter, representative methods, devices,
and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a fluorophore" includes a plurality of such images,
and so forth.
Unless otherwise indicated, all numbers expressing quantities, properties, and so forth used in the specification and
claims are to be understood as being modified in all instances
by the term "about". Accordingly, unless indicated to the
contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending
upon the desired properties sought to be obtained by the
presently-disclosed subject matter.
As used herein, the term "about," when referring to a value
or to an amount of mass, weight, time, volume, concentration
or percentage is meant to encompass variations of in some
embodiments ±50%, in some embodiments ±40%, in some
embodiments ±30%, in some embodiments ±20%, in some
embodiments ±10%, in some embodiments ±5%, in some
embodiments ±1%, in some embodiments ±0.5%, and in
some embodiments ±0.1% from the specified amount, as such
variations are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "1 0" is disclosed, then "about 10" is
also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, iflO and
15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
The term "physiologically functional derivative" means
any pharmaceutically acceptable derivative of a compound of
the present disclosure. For example, an amide or ester of a
compound of formula (I) or of a compound of formula (II),
which upon administration to a subject, particularly a mammal, is capable of providing, either directly or indirectly, a
compound of the present disclosure of an active metabolite
thereof.
The terms "treatment" or "treating" refer to the medical
management of a subject with the intent to cure, ameliorate,
stabilize, or prevent a condition or disorder (e.g., retinal degradation). This term includes active treatment, that is, treatment directed specifically toward the improvement of a condition, and also includes causal treatment, that is, treatment
directed toward removal of the cause of the associated condition. In addition, this term includes palliative treatment, that
is, treatment designed for the relief of symptoms rather than

DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document. Modifications to embodiments described in this document, and
other embodiments, will be evident to those of ordinary skill
in the art after a study of the information provided in this
document. The information provided in this document, and
particularly the specific details of the described exemplary
embodiments, is provided primarily for clearness of understanding and no unnecessary limitations are to be understood
therefrom. In case of conflict, the specification of this document, including definitions, will control.
The presently-disclosed subject matter is illustrated by
specific but non-limiting examples throughout this description. The examples may include compilations of data that are
representative of data gathered at various times during the
course of development and experimentation related to the
present invention(s). Each example is provided by way of
explanation of the present disclosure and is not a limitation
thereon. In fact, it will be apparent to those skilled in the art
that various modifications and variations can be made to the
teachings of the present disclosure without departing from the
scope of the disclosure. For instance, features illustrated or
described as part of one embodiment can be used with another
embodiment to yield a still further embodiment.
All references to singular characteristics or limitations of
the present disclosure shall include the corresponding plural
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the curing of the condition; preventative treatment, that is,
treatment directed to minimizing or partially or completely
inhibiting the development of symptoms or disorders of the
associated condition; and supportive treatment, that is, treatment employed to supplement another specific therapy
directed toward the improvement of the associated disease,
pathological condition, or disorder.
With regard to administering the compound, the term
"administering" refers to any method of providing a composition and/or pharmaceutical composition thereof to a subject. Such methods are well known to those skilled in the art
and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal
administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration,
intracerebral administration, rectal administration, and
parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, subcutaneous administration, intravitreous administration, including via intravitreous sustained
drug delivery device, intracameral (into anterior chamber)
administration, suprachoroidal injection, subretinal administration, Subconjunctival injection, sub-Tenon's administration, peribulbar administration, Transscleral drug delivery,
administration via topical eye drops, and the like. Administration can be continuous or intermittent. In various aspects, a
preparation can be administered therapeutically; that is,
administered to treat an existing disease or condition (e.g.,
exposure to OP compounds). In further various aspects, a
preparation can be administered prophylactically; that is,
administered for prevention of a disease or condition.
The term "effective amount" refers to an amount that is
sufficient to achieve the desired result or to have an effect on
an undesired condition. For example, a "therapeutically
effective amount" refers to an amount that is sufficient to
achieve the desired therapeutic result or to have an effect on
undesired symptoms, but is generally insufficient to cause
adverse side effects. The specific therapeutically effective
dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the
severity of the disorder; the specific composition employed;
the age, body weight, general health, sex and diet of the
patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed;
the duration of the treatment; drugs used in combination or
coincidental with the specific compound employed and like
factors well known in the medical arts. For example, it is well
within the skill of the art to start doses of a compound at levels
lower than those required to achieve the desired therapeutic
effect and to gradually increase the dosage until the desired
effect is achieved. If desired, the effective daily dose can be
divided into multiple doses for purposes of administration.
Consequently, single dose compositions can contain such
amounts or submultiples thereof to make up the daily dose.
The dosage can be adjusted by the individual physician in the
event of any contraindications. Dosage can vary, and can be
administered in one or more dose administrations daily, for
one or several days. Guidance can be found in the literature
for appropriate dosages for given classes of pharmaceutical
products. In further various aspects, a preparation can be
administered in a "prophylactically effective amount"; that is,
an amount effective for prevention of a disease or condition.
The terms "subject" or "subject in need thereof' refer to a
target of administration, which optionally displays symptoms
related to a particular disease, condition, disorder, or the like.
The subject(s) of the herein disclosed methods can be human
or non-human (e.g., primate, horse, pig, rabbit, dog, sheep,

goat, cow, cat, guinea pig, rodent, and non-mmals). The
term "subject" does not denote a particular age or sex. Thus,
adult and newborn subjects, as well as fetuses, whether male
or female, are intended to be covered. The term "subject"
includes human and veterinary subjects.
As will be recognized by one of ordinary skill in the art, the
terms "suppression," "suppressing," "suppressor," "inhibition," "inhibiting" or "inhibitor" do not refer to a complete
elimination of angiogenesis in all cases. Rather, the skilled
artisan will understand that the term "suppressing" or "inhibiting" refers to a reduction or decrease in angiogenesis. Such
reduction or decrease can be determined relative to a control.
In some embodiments, the reduction or decrease relative to a
controlcanbeabouta 1,2,3,4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14,
15, 16,17, 18, 19,20,21,22,23,24,25,26,27,28,29,30,31,
32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,
49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,
66,67,68,69, 70, 71, 72,73, 74, 75, 76, 77,78, 79,80,81,82,
83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,
or 100% decrease.
In some exemplary embodiments, the presently-disclosed
subject matter includes methods for treating retinal damage
and/or retinal degeneration. Indeed, some methods of the
present disclosure comprise administering to a subject in
need thereof an effective amount of a composition for treating
retinal damage and/or degradation.
In some embodiments the composition comprises a
nucleoside and/or a nucleoside reverse transcriptase inhibitor
(NRTI). Further, in some embodiments, the composition is a
pharmaceutical composition comprising a nucleoside and/or
a NRTI compound as well as a pharmaceutically acceptable
earner.
As discussed herein, in some exemplary methods of the
present disclosure, the administered composition is a composition comprising a nucleoside and/or NRTI. Thus, exemplary
compositions are comprised of compounds including, but not
limited to, stavudine (d4T), lamivudine (3TC), cordycepin,
azidothymidine (AZT), abacavir (ABC), chemical derivatives thereof (e.g., methoxy-derivatives to abrogate phosphorylation), and the like. Other possible compounds include, for
example, those described in U.S. Pat. No. 6,514,979 to
Heredia et a!. Those of ordinary skill in the art will also
recognize further nucleosides and/or NRTis, as described
herein, that can be used in the compositions and methods of
this disclosure.
In some embodiments a method of the present disclosure
comprises inhibiting activation of one or more physiological
processes by Alu RNA. As disclosed herein, Alu RNA (including Alu repeat RNA in human cells and B1 and B2,
Alu-like element repeat RNAs) increases are associated with
cells that are associated with certain conditions of interest.
For example, an Alu RNA increase is associated with the
retinal pigment epithelium (RPE) cells of eyes with geographic atrophy. This increase of Alu RNA induces the death
ofRPE cells. Methods and compositions disclosed herein can
treat RPE degradation, thereby treating conditions associated
with such cell death.
In some embodiments, a method of the present disclosure
comprises inhibiting the activation of at least one inflammasome. In certain embodiments, the at least one inflmasome
is selected from an NLRP3 inflammasome, a 1L-1 beta
inflammasome, and a combination thereof. In some embodiments, the inhibiting one or more inflammasomes of a cell
includes administering an inhibitor (composition) to the cell
and/or to a subject, wherein the cell is the cell of a subject. For
compositions comprising an inhibitor, an inhibitor as
described herein can be, for example, a polypeptide inhibitor
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(including an oligonucleotide inhibitor), a small molecule
inhibitor, and/or an siRNA inhibitor.
Moreover, some exemplary methods of administering the
present composition(s) can inhibit inflammation by LPS/
ATP, inflammasome activation by LPS/ATP, inflammasome
activation by Alu RNA, and/or nigericin-induced inflammasome activation. Exemplary methods can also treat retinal
degradation and/or other retinal damage by reducing mitochondrial reactive oxygen species, particularly as caused by
Alu RNA expression, by blocking entry via the P2X7 receptor, and/or by reducing ATP-induced cell permeability.
In some embodiments, a method of the present disclosure
comprises treating retinal damage by inhibiting a particular
action in a cell. In some embodiments, the cell is selected
from an RPE cell, a retinal photoreceptor cell, or a choroidal
cell. In some embodiments, the cell is an RPE cell. In some
embodiments, the cell is the cell of a subject. In some embodiments, the cell is a cell of a subject having, suspected of
having, or at risk of having a condition of interest. In some
embodiments, the cell is a cell of a subject having, suspected
of having, or at risk of having age-related macular degeneration. In some embodiments, the cell is a cell of a subject
having, suspected of having, or at risk of having geographic
atrophy. In some embodiments, the cell is a cell of a subject
having, suspected of having, or at risk of having geographic
atrophy and the cell is an RPE cell. In some embodiments, a
subject having age-related macular degeneration can be
treated using methods and compositions as disclosed herein.
Thus, as used herein with reference to a polypeptide being
inhibited, "of a cell" refers to a polypeptide that is inside the
cell (inside the cell membrane), on the cell (in the cell membrane, presented on the cell membrane, otherwise on the cell),
or outside of a cell, but insofar as the polypeptide is outside of
the cell, it is in the extracellular milieu such that one of
ordinary skill in the art would recognize the polypeptide as
being associated with the cell. For example, VDACl,
VDAC2, caspase-8, NFKB, or a polypeptide of an inflammasome (e.g., NLRP3, PYCARD, caspase-1) could be in the
cell. For another example, NLRP3 could be in the cell or on
the cell.
As described herein, the presently-disclosed subject matter
further includes pharmaceutical compositions comprising the
compounds described herein together with a pharmaceutically acceptable carrier.
The term "pharmaceutically acceptable carrier" refers to
sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to
use. Proper fluidity can be maintained, for example, by the
use of coating materials such as lecithin, by the maintenance
of the required particle size in the case of dispersions and by
the use of surfactants. These compositions can also contain
adjuvants such as preservatives, wetting agents, emulsifying
agents and dispersing agents. Prevention of the action of
microorganisms can be ensured by the inclusion of various
antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable
to include isotonic agents such as sugars, sodium chloride and
the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such
as aluminum mono stearate and gelatin, which delay absorption. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such
as polylactide-polyglycolide, poly(orthoesters) and poly( anhydrides). Depending upon the ratio of drug to polymer and
the nature of the particular polymer employed, the rate of
drug release can be controlled. Depot injectable formulations

are also prepared by entrapping the drug in liposomes or
microemulsions which are compatible with body tissues. The
injectable formulations can be sterilized, for example, by
filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions
which can be dissolved or dispersed in sterile water or other
sterile injectable media just prior to use. Suitable inert carriers
can include sugars such as lactose.
Suitable formulations include aqueous and non-aqueous
sterile injection solutions that can contain antioxidants, buffers, bacteriostats, bactericidal antibiotics and solutes that render the formulation isotonic with the bodily fluids of the
intended recipient; and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents.
The compositions can take such forms as suspensions,
solutions or emulsions in oily or aqueous vehicles, and can
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient
can be in powder form for constitution with a suitable vehicle,
e.g., sterile pyrogen-free water, before use.
The formulations can be presented in unit-dose or multidose containers, for example sealed ampoules and vials, and
can be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of sterile liquid carrier immediately prior to use.
For oral administration, the compositions can take the form
of, for example, tablets or capsules prepared by a conventional technique with pharmaceutically acceptable excipients
such as binding agents (e.g., pregelatinized maize starch,
polyvinylpyrrolidone or hydroxypropyl methylcellulose);
fillers (e.g., lactose, microcrystalline cellulose or calcium
hydrogen phosphate); lubricants (e.g., magnesium stearate,
talc or silica); disintegrants (e.g., potato starch or sodium
starch glycollate ); or wetting agents (e.g., sodium Iaury! sulphate). The tablets can be coated by methods known in the art.
Liquid preparations for oral administration can take the
form of, for example, solutions, syrups or suspensions, or
they can be presented as a dry product for constitution with
water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional techniques with
pharmaceutically acceptable additives such as suspending
agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifYing agents (e.g. lecithin or acacia);
non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g.,
methyl or propyl-p-hydroxybenzoates or sorbic acid). The
preparations can also contain buffer salts, flavoring, coloring
and sweetening agents as appropriate. Preparations for oral
administration can be suitably formulated to give controlled
release of the active compound. For buccal administration the
compositions can take the form of tablets or lozenges formulated in conventional manner.
The compositions can be formulated as eye drops. For
example, the pharmaceutically acceptable carrier may comprise saline solution or other substances used to formulate eye
drop, optionally with other agents. Thus, eye drop formulations permit for topical administration directly to the eye of a
subject.
The compositions can also be formulated as a preparation
for implantation or injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or
ion exchange resins, or as sparingly soluble derivatives (e.g.,
as a sparingly soluble salt). The compounds can also be formulated in rectal compositions, creams or lotions, or transdermal patches.
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The presently-disclosed subject matter further includes a
kit that can include a compound or pharmaceutical composition as described herein, packaged together with a device
useful for administration of the compound or composition. As
will be recognized by those or ordinary skill in the art, the
appropriate administration-aiding device will depend on the
formulation of the compound or composition that is selected
and/or the desired administration site. For example, if the
formulation of the compound or composition is appropriate
for injection in a subject, the device could be a syringe. For
another example, if the desired administration site is cell
culture media, the device could be a sterile pipette.
Moreover, NRTis of the present disclosure are a diverse,
widely used, inexpensive class of small molecules, with
extensive pharmacokinetic and safety data collected over the
past several decades of human use; NRTis are therefore ripe
for drug repurposing. As such, the present disclosure provides
a novel and broadly applicable basis for use of one or more
NRTis by addressing major unmet medical needs.
As briefly described above, age-related macular degeneration is a disease that affects tens of millions of people worldwide, and there is no effective treatment for AMD (Ambati
and Fowler, 2012). Similarly, graft-versus host disease is the
major obstacle preventing successful tissue transplant (Ferrara et a!., 2009); and sterile liver inflammation is a major
contributor to drug-induced liver injury and steatohepatitis, a
major determinant of fibrosis and carcinogenesis (Kubes and
Mehal, 2012). Thus, some methods and/or compounds of the
present disclosure are intended to treat age-related macular
degeneration, graft-versus host disease, and/or sterile liver
inflammation by administering, in some embodiments, a
compound comprising at least one NRTI, as provided in the
present disclosure.
Since inflmasome inhibition by NRTis can be achieved
without phosphorylation of a particular NRTI, the use of
me-d4T or other phosphorylation-incompetent nucleoside
analogs, as provided herein, should avoid therapeutic-limiting toxicities associated with NRTI-triphosphate-mediated
polymerase inhibition (Lewis et a!., 2003). Accordingly, in
some embodiments, the present disclosure is directed to
methods for treating retinal disease by administering me-d4 T
or another phosphorylation-incompetent nucleoside analog
to a subject in need thereof.
Further, in certain embodiments, the present disclosure
provides methods for treating retinal damage, comprising:
administering an effective amount of a composition to a subject in need thereof, wherein the composition comprises an
NRTI. In some embodiments, the NRTI is selected from the
group consisting of stavudine (d4T), lamivudine (3TC),
cordycepin, azidothymidire (AZT), abacavir (ABC), or
derivatives or combinations thereof.
In some embodiments, the presently disclosed subject matter provides methods for protecting an RPE cell, a retinal
photoreceptor cell, a choroidal cell, or a combination thereof
comprising at least the step of administering a composition
that comprises at least one nucleoside analog or NRTI,
according to the present disclosure, to a subject in need
thereof.
Moreover, in some embodiments, the present disclosure is
directed to the synthesis and/or use of one or more compounds of Formula I, Formula II, Formula III, Formula IV,
and/or Formula IV:
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-continued

drug-induced lung inflammation, contact dermatitis, leprosy,
Burkholderia cenocepacia infection, respiratory syncitial
virus infection, psoriasis, scleroderma, reactive arthritis, cystic fibrosis, syphilis, Sjogren's syndrome, inflammatory joint
disease, non-alcoholic fatty liver disease, cardiac surgery
(peri-/post-operative inflammation), acute and chronic organ
transplant rejection, acute and chronic bone marrow transplant rejection, tumor angiogenesis, and/or any combination
thereof.
Moreover, in some embodiments, the present disclosure
provides that non-canonical NRTI function, independent of
chain termination, prevents P2X7-dependent blindness,
graft-versus-host disease and/or sterile inflammation.
Accordingly, the present disclosure is directed, in certain
embodiments, to methods of preventing P2X7-dependent
blindness, graft-versus-host disease and/or inflammation in a
subject by administering an effective amount of at least one
NRTI, as described herein, to subject in need thereof.
Further, in certain embodiments, the methods and compositions of the present disclosure inhibit (i) inflammasome
activation by Alu RNA associated with a cell; (ii) inflammation by LPS/ATP, (iii) inflammasome activation by LPS/ATP,
(iv) nigericin-induced inflammasome activation, and/or combinations thereof. And in some embodiments, the inflammasome is selected from the group consisting of a NLRP3
inflammasome and/or a 1L-1 beta inflammasome. Additionally, some embodiments of the methods of the present disclosure may include, for example, the steps of (i) blocking entry
via a P2X7 receptor associated with a cell; (ii) reducing
mitochondrial reactive oxygen species caused by Alu RNA
expression; and/or (iii) reducingATP-induced cell permeability of a cell. And a cell contemplated in the present disclosure
may include, for example, an RPE cell, a retinal photoreceptor cell, a choroidal cell, or any combination thereof.
Further, NRTis are mainstay therapeutics for HIV, and they
block retrovirus replication. Alu RNA, an endogenous retroelement that also requires reverse transcriptase (RT) for its
life cycle, activates the NLRP3 inflammasome to cause cell
death of the retinal pigment epithelium in geographic atrophy,
which is the untreatable form of age-related macular degeneration that blinds millions of individuals. Moreover, the
inventors of the present disclosure have found that NRTis, as
a class, are novel inhibitors of the NLRP3 inflammasome.
And, surprisingly, this effect is independent of reverse transcriptase inhibition.
Thus, the inventors of the present disclosure have found
that the NRTis d4T, AZT, ABC, and 3TC block Caspase 1
activation by Alu RNA, as does 5'-methoxy-d4T, which does
not inhibit reverse transcriptase. Further, the present inventors have found that AZT is not phosphorylated in thymidine
kinase-deficient cells but still blocks LPS/ATP-induced interleukin-1 beta secretion; that NRTis block P2X7 -dependent
YOPR0-1 dye uptake in mouse models of geographic atrophy, graft-versus-host disease, and sterile liver inflammation;
and that NRTis are novel inhibitors of the NLRP3 inflammasome independent of canonical reverse transcriptase inhibition. Accordingly, NRTis are ripe for drug repurposing in a
variety of P2X7 -driven diseases.
NRTis were first discovered to be anti-viral compounds in
1974 (Ostertag et a!., 1974), and are widely used to treat
human immunodeficiency virus (HIV). The canonical
mechanism of action of NRTis is via chain termination of
DNA synthesis from a viral RNA template, thereby interfering with the viral life cycle of reverse transcriptase-dependent
v1ruses.
Age-related macular degeneration (AMD) is a leading
cause of blindness in the elderly worldwide (Ambati et a!.,

(V)
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15

and/or to any salt, particularly any pharmaceutically acceptable salt, any solvate, and/or any physiological derivative
thereof. In some embodiments, "n" of Formula IV is any
integer, and in a particular embodiment, n is 11.
Further, the present disclosure provides uses of a compound of any of Formulas (I), (II), (III), (IV) and/or (IV), or
any combination thereof, in the preparation or manufacture of
a pharmaceutical composition, such as a drug and/or medicine, especially a composition for the treatment of retinal
damage and/or retinal degeneration in a mammal. In some
embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of any ofFormulas
(I), (II), (III), (IV) and/or (IV), any salt, particularly any
pharmaceutically acceptable salt, any solvate, and/or any
physiological derivative thereof, together with a pharmaceutically acceptable carrier.
In certain embodiments, the methods and compositions of
the present disclosure inhibit graft-versus-host disease,
chronic pain, proliferative vitreoretinopathy, glaucoma, rheumatoid arthritis, multiple sclerosis, bipolar disorder, major
depressive disorder, renal fibrosis, nephritis, pulmonary
fibrosis, Huntington's disease, osteoporosis, chronic lymphocytic leukemia, anxiety disorders, pulmonary tuberculosis,
osteoporosis in post-menopausal women and fracture
patients, systemic lupus erythematosus, chronic inflammatory and neuropathic pain, autosomal dominant polycystic
kidney disease, spinal cord injury, Alzheimer's disease, neuropathic pain, hypertension, varicose veins, type I diabetes,
type II diabetes, gout, autoimmune hepatitis, graft vascular
injury, atherosclerosis, thrombosis, metabolic syndrome,
salivary gland inflammation, traumatic brain injury, ischemic
heart disease, ischemic stroke, Parkinson's disease, melanoma, neuroblastoma, prostate, breast, skin, and thyroid cancers, tubular early gastric cancer, neuroendocrine cancer,
mucoid colon cancer, colon cancer; high-grade urothelial
carcinoma, kidney clear cell carcinoma, undifferentiated
ovary carcinoma, papillary intracystic breast carcinoma,
gram negative sepsis, infectious Pseudomonas aeruginosa,
Vibrio cholera, Legionella spp., Francis ella spp., and Leishmania spp. Chlamydia spp., cryopyrinopathies; keratitis,
acne vulgaris, Crohn's disease, ulcerative colitis, irritable
bowel syndrome, insulin resistance, obesity, hemolytic-uremic syndrome, polyoma virus infection, immune complex
renal disease, acute tubular injury, lupus nephritis, familial
cold autoinflammatory syndrome, Muckle-Wells syndrome
and neonatal onset multisystem inflammatory disease,
chronic infantile neurologic cutaneous and articular autoinflammatory diseases, renal ischemia-perfusion injury, glomerulonephritis, cryoglobulinemia, systemic vasculitides, IgA
nephropathy, malaria, helminth parasites, septic shock, allergic asthma, hay fever, chronic obstructive pulmonary disease,
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2003; Ambati and Fowler, 2012). In the more prevalent and
untreatable dry form of AMD, overabundance of non-coding
Alu RNAs causes blindness by inducing cell death of the
retinal pigment epithelium (Dridi eta!., 2012; Kaneko eta!.,
2011; Tarallo et a!., 2012). Alu sequences are non-coding
retrotransposons that, like HIV, rely on reverse transcriptase
for their life cycle (Batzer and Deininger, 2002; Dewannieux
eta!., 2003).
Alu RNA mediates RPE cell death via activation of
Caspase 1 and the NLRP3 inflammasome (Tarallo et a!.,
2012). The present disclosure provides that a reverse transcriptase inhibitor, such as stavudine (d4T; 2'3' dideoxythymidine; Zerit, Bristol-Myers Squibb), which is FDA-approved for the treatment ofHIV, prevents Caspase 1 cleavage
to its active 20 kDa form (Hentze eta!., 2003; Yamin eta!.,
1996) inprimaryhuman(FIG. 34) andmouseRPE cells (FIG.
44) without reducing Alu RNA levels (FIG. 45). Further, the
present disclosure shows that d4T also blocks phosphorylation ofiRAK4, a kinase downstream of the MyD88 adaptor
that mediates Alu-induced RPE cell death (Tarallo et a!.,
2012), in human and mouse RPE cells (FIG. 34 and FIG. 44).
The inventors of the present disclosure have also found that
other NRTis, including the anti-HIV drugs azidothymidine
(AZT; 3'-azido-2',3'-dideoxythymidine; Retrovir, ViiV
Healthcare), lamivudine (3TC; 2'3' dideoxycytidine; Zeffix,
GlaxoSmithKline) and abacavir (ABC; a di -deoxyguanosine
analog; Ziagen, ViiV Healthcare ), also block Caspase-1
cleavage induced by Alu RNA (FIG. 35).
Additionally, the present disclosure provides that d4T and
AZT prevent RPE degeneration in the Alu RNA-induced
mouse model of dry AMD. (Kaneko eta!., 2011; Tarallo eta!.,
2012) Moreover, it has been found that mice receiving daily
oral administration of d4T blocked RPE degeneration after
sub-retinal injection of a plasmid expressing Alu RNA (FIG.
36), as did intraperitoneal administration of AZT (FIG. 37).
In order to test whether reverse transcriptase inhibition was
required for inflammasome blockade by d4T, a 5' 0-methylmodified version of d4T (5'-0CH3-d4T; me-d4T) was synthesized (FIG. 20; FIG. 25, FIG. 36, FIG. 27, FIG. 28).
Accordingly, in some embodiments, the present disclosure is
directed to methods for synthesizing a 5' 0-methyl-modified
version of d4T as provided herein.
Only the triphosphate version of nucleoside analogs inhibit
reverse transcriptase; the methyl modification at the 5' position prevents phosphorylation and thus formation of nucleoside triphosphate (Nykanen eta!., 2001). Accordingly, like
d4 T, me-d4 T also blocks Caspase-1 activation in human RPE
cells (FIG. 21).
The present inventors have confirmed that me-d4 T does not
inhibit reverse transcriptase: and, in contrast to uumodified
d4T, me-d4T does not block lentivirus replication (FIG. 22).
Also, the triphosphate metabolite of di-deoxy nucleoside analogs caused depletion of mitochondrial DNA; and consistent
with the idea that me-d4T is not phosphorylated, it has been
found that d4T, but not me-d4T reduces mtDNA levels. (FIG.
23). Me-d4T also prevents Alu-induced RPE degeneration in
mice (FIG. 24). These data indicate that d4T can block
Caspase-1 activation and RPE degeneration independent of
reverse transcriptase inhibition.
Further, the present inventors also tested whether NRTis
blocked inflammasome activation by LPS/ATP, which is not
known to signal via reverse transcriptase (Mariathasan et a!.,
2004; Mariathasan eta!., 2006; Martinon eta!., 2002). It was
found that d4 T inhibited LPS/ATP-induced Caspase-1 maturation in primary mouse bone marrow-derived macrophages
(FIG. 38) as detected by Western blot.

Caspase-1 directly processes interleukin 1 beta (IL-l beta)
upon LPS/ATP stimulation; d4T also blocks secretion of
mature IL-l beta in these cells (FIG. 39). To determine
whether LPS/ATP-induced inflammasome activation can be
inhibited without RT inhibition, the present inventors utilized
thymidine kinase-deficient (Raji/TK-) and -expressing (Raji/
TK+) cells (Balzarini eta!., 1989). After addition of AZT,
TK+, but not TK- cells, the present inventors producedAZTtriphosphate (AZT-TP), the AZT metabolite required for RT
inhibition (FIG. 40; FIG. 46, FIG. 47, FIG. 48, FIG. 49, FIG.
50). Even though AZT was not phosphorylated in TK- cells,
AZT still inhibited LPS/ATP-induced interleukin-1 beta
maturation (FIG. 41), indicating that AZT did not inhibit
interleukin -1 beta maturation via reverse transcriptase inhibition.
Alu RNA (Kerur et a!., 2013) and LPS/ATP (Qu et a!.,
2011) activate the inflammasome via the ATP receptor P2X7.
The present inventors therefore hypothesized that d4 T blocks
P2X7 or some P2X7-dependent pathway. First, testing was
conducted to determine whether d4T acts upstream ofP2X7
by modulating ATP levels; however, d4T does not block
release of ATP to cell culture media induced by Alu RNA
(FIG. 42).
Next, testing was conducted to determine whether d4T
directly antagonizes P2X7 function: uponATP binding, cellsurface P2X7 forms non-selective cation channels that mediate inflammasome activation (Kahlenberg and Dub yak, 2004;
Petrilli et a!., 2007). However, d4T did not significantly
modulate P2X7 cation channel function as monitored by
patch clamp analysis ofHEK293 stable cell lines expressing
either the human or rat P2X7 receptor (Humphreys et a!.,
2000).
Finally, P2X7 activation is associated with the formation of
a large pore that is permeable to molecules of up to -1000 Da
(Adinolfi eta!., 2005; Cheewatrakoolpong eta!., 2005; Surprenant eta!., 1996). It was found that d4T, and alsoAZT and
3 TC, inhibited P2X7 -dependent uptake of the fluorescent dye
YO-PRO! (M.W. Da) in human P2X7-overexpressing
HEK293 stable cell line (FIG. 43) after addition of the selective P2X7 agonist bzATP.
Consistent with the idea that NRTis block Alu-induced
P2X7-mediated inflammasome activation via a mechanism
involving dye uptake, Alu RNA-induced Caspase-1 activation was inhibited by a small peptide that blocks P2X7 -mediated dye uptake and LPS/ATP-induced inflammasome activation, but not cation flux (Pelegrin and Surprenant, 2006)
(FIG. 51). On the other hand, Alu-induced Caspase-1 activation was not inhibited by calmidazolium, which selectively
blocks P2X7-mediated cation flux but not dye uptake (FIG.
52).
Furthermore, the intracellular C-terminus ofP2X7 governs
P2X7 -associated dye uptake, and a version of d4T that is not
cell permeable (Agarwal et a!., 2011) does not block
caspase-1 activation by Alu RNA (FIG. 53, FIG. 32). Consistent with antagonism at or downstream ofP2X7, but upstream
of mitochondrial dysfunction, d4T blocks mitochondrial
ROS (mtROS) production, which are produced upon LPS/
ATP stimulation (Adinolfi et a!., 2005; Cruz et a!., 2007;
Garcia-Marcos eta!., 2005; Nakahira eta!., 2011) and Alu
overexpression (Tarallo eta!., 2012) was measured by MitoSOx assay (FIG. 54). Finally, d4T does not prevent P2X7independent interleukin 1-beta secretion in PMA-primed
THP-1 cells treated with crystalline monosodium urate (FIG.
11) (Martinon eta!., 2006; Riteau eta!., 2012).
To explore the potential therapeutic relevance of NRTis
beyond the Alu-induced model of geographic atrophy (GA),
it was hypothesized that ifNRTis function as generic inflam-
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masome inhibitors, then they might be broadly useful in other
animal models of disease that are also driven by P2X7. In the
NLRP3 inflammasome- and P2X7-driven graft-versus-host
disease model (Jankovic eta!., 2013; Wilhelm eta!., 2010),
treatment of mice receiving allogeneic bone marrow and T
cells with d4 T showed improved survival compared to saline
treated controls (30-70% vs. 0%). Furthermore, in the
NLRP3- and P2X7 -driven model of sterile inflammation
(McDonald eta!., 201 0), d4 T reduced neutrophil migration to
the focus of liver injury.
Interestingly, it has been shown that P2X7 -dependent pore
function alone can influence phenotype (Sorge eta!., 2012).
However, at present, there are not any FDA-approved drugs
that selectively target downstream P2X7 signaling and not ion
channel activation. Therefore, NRTis could be valuable both
clinically and experimentally in the selective targeting of
P2X7 function.
A role for P2X7 in regulating HIV replication was recently
proposed (Hazleton et a!., 2012), and HIV patients have
increased plasma IL-lS levels (Ahmad eta!., 2002; Iannello
eta!., 201 0), which decrease after treatment with NRTI-containing highly active anti-retroviral therapy (Stylianou eta!.,
2003 ). Notably, reduction of plasma IL-18 levels by NRTI
treatment of HIV-1 infected patients did not significantly
associate with viral load or CD4+ T-cell counts (David et a!.,
2000), indicating that NRTis can dampen IL-18 levels before
inhibition of viral replication occurs. IL-18 maturation
requires pro-ILlS cleavage by active Caspase 1, which typically also requires P2X7 activation. Thus, the methods and
experiments of the present disclosure are consistent with the
idea that NRTis can modulate HIV-induced cytokine expression independent of reverse transcriptase inhibition.
In some embodiments, d4T prevents RPE degeneration
induced by Alu RNA in wild type mice. As shown in FIG. 1,
sub-retinal Alu RNA administration to mice causes RPE
degeneration in a mouse model of age-related macular degeneration. Indeed, as shown, d4T co-delivered to the vitreous
humor of wild type mice prevents Alu RNA-induced RPE cell
death in a dose-dependent manner at one week after delivery.
The top row of FIG. 1 provides an ocular fundus photograph
of mice receiving control PBS, or Alu RNA treatment, with or
without increasing amounts of d4T (left to right). Arrows
denote depigmented regions ofRPE cell death, which resolve
at highest dose of d4T. The bottom row of FIG. 1 shows an
RPE flat mount, stained for intercellular junctions (Z0-1) in
red that are disrupted upon Alu RNA administration, but
restored to healthy RPE morphology/intercellular junctions
at highest dose of d4 T.
Meanwhile, in certain embodiments, d4T protects against
cytotoxicity induced by plasmid expressingAlu RNA in vitro.
FIG. 2 shows that human (HeLa) cells treated with an
enforced expression plasmid for Alu RNA (pAluA) for
denoted amounts of time exhibited profoundly reduced
viability compared to a null plasmid (pUC19), as monitored
by MTS proliferation assay, and that d4T co-administration
prevented cell death induced by Alu overexpression.
In some exemplary embodiments, d4T does not rescue
cytotoxicity via reduction inAlu RNA levels. As presented in
FIG. 3, primary human RPE cells treated with antisense oligonucleotides targeting DICERl (Dcr as) (lane 3 (third lane
from left)) show increased Alu RNA levels in the nuclear
compartment compared to control antisense oligonucleotides
(Ctr as) (lane 1 (leftmost)), monitored by Northern blotting
using an Alu-specific probe. Meanwhile, co-administration
ofd4T (lanes 2 and 4) does notreduceAlu RNA levels. FIG.
3 shows u6 (bottom row) as a loading control for nuclear
fraction.

Moreover, in some embodiments, d4 T does not reduce Alu
RNA levels. For example, primary human RPE cells may be
transfected withAlu RNA, with or without d4 T. (FIG. 4) And,
as presented in FIG. 4, co-administration of d4T does not
change Alu RNA levels at 1, 4, or 24 hours after transfection
in the nuclear fraction, as detected by Northern blotting using
anAlu-specific probe. U6 (bottom row) is shown as loading
control for nuclear fraction in FIG. 4.
The present disclosure further provides that, in some
embodiments, d4T inhibits inflammasome activation by Alu
RNA. Indeed, Alu RNA causes NLRP3 inflammasome activation, which is marked by processing of the enzyme Caspase
1, and FIG. 5 provides a Western blot showing thatAlu RNA
causes Caspase-1 maturation in primary human RPE cells at
24 hours after Alu administration (Top, Lane 2, lower band),
which is blocked by co-treatment with d4T (1 00 uM; Lane 3).
The bottom row in FIG. 5 is a vinculin loading control.
In certain embodiments, 3TC inhibits inflarnmasome activation by Alu RNA. Indeed, Alu RNA causes NLRP3 inflammasome activation, which is marked by processing of the
enzyme Caspase 1. FIG. 6 is a Western blot showing thatAlu
RNA causes Caspase-1 maturation in primary human RPE
cells at 24 hours after Alu administration (top, lane 2, lower
band), which is blocked with co-treatment with 3 TC (20-1 00
uM; lane 3). On the bottom, the loading control, vinculin, is
visible.
Next, FIG. 7 provides evidence of AZT, cordycepin, and
abacavir inhibition of inflammasome activation by Alu RNA.
Indeed, Alu RNA causes NLRP3 inflammasome activation,
which is marked by processing of the enzyme Caspase 1. FIG.
7 is a Western blot showing that Alu RNA causes Caspase-1
maturation in primary human RPE cells at 24 hours after Alu
administration (top, lane 2, lower band), which is blocked
with co-treatment with azidothymidine (AZT), cordycepin,
and abacavir (ABC) (50-100 uM; Lanes 3-8). Again, the
loading control vinculin is shown on the bottom.
In certain embodiments, the present disclosure provides
that d4T inhibits inflammasome activation by LPS/ATP. As
such, FIG. 8 provides a gel showing that primary human RPE
cells treated with LPS/ATP, a classic inflammasome activator,
exhibit increased Casp-1 activation, and phosphorylation of
IRAK4, which is also a marker of inflammasome signaling
via the cell surface receptor adaptor protein MyD88. Moreover, as shown in FIG. 8, d4T (25/100 uM) blocks Casp-1
activation and IRAK4 phosphorylation induced by LPS/ATP.
The loading control in FIG. 8 is vinculin. Furthermore, as
shown, LPS andATP activate the NLRP3 inflammasome only
in combination, thus treatment with one or the other alone is
useful as a control for this experiment.
The present disclosure further provides that, in exemplary
embodiments, d4T and other NRTis reduce inflarnmasome
activation byLPS/ATP.AspresentedinFIG. 9, d4T, 3TC, and
cordycepin (at 100 uM), all di-deoxy nucleoside reverse transcriptase inhibitors, inhibit Caspase-1 activation (active p20
band, top) and IL-18 maturation (bottom) induced by LPS/
ATP. To produce FIG. 9, cell culture supernatants were collected after (i) no treatment, (ii) LPS treatment, or (iii) LPS/
ATP treatment of mouse bone marrow-derived macrophages
and run on Western blotting probing with antibodies for
Caspase-1 and IL-18.
In some embodiments of the present disclosure, d4T inhibits nigericin-induced inflammasome activation. Per FIG. 10,
d4T (1 00, 250 uM) inhibits IL-l beta maturation (top, 18 and
22 kDa forms) and Caspase-1 activation (active p20 band,
bottom) induced by nigericin. Cell culture supernatants were
collected after (i) no treatment, (ii) LPS treatment, or (iii)
LPS/nigericin treatment of mouse bone marrow-derivedmac-
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rophages, and run on Western blotting probing with antibodies foriL-1 beta and Caspase-1. FIG. 10 shows the results of
these efforts.
Additionally, in some embodiments, d4T does not inhibit
IL-l beta secretion from PMA-differentiated THP-1 monocytes induced by MSU. Human THP-1 monocytes were differentiated into macrophages with PMA. As shown in FIG.
11, treatment with monosodium urate (MSU), a known
inflammasome activator, increased IL-l beta secretion compared to non-treated cells, whereas d4T co-administration at
a range of doses (25-1000 uM) did not significantly affect
IL-l beta secretion. Further, d4T does not block MSU-induced IL-l beta secretion as determined by ELISA (n=3-4).
In certain embodiments, d4T and other nucleoside reverse
transcriptase inhibitors do not inhibit IL-l beta secretion from
PMA-differentiated THP-1 monocytes induced by MSU. To
illustrate this, human THP-1 monocytes were differentiated
into macrophages with PMA. Treatment with MSU increased
IL-l beta secretion compared to non-treated cells. (FIG. 12)
Meanwhile d4T, 3TC, or cordycepin (all are di-deoxy nucleotide analogs) co-administration at a range of doses (25-1 000
uM) did not significantly affect IL-l beta secretion, as shown
in FIG.12.
Next, in some embodiments, d4T reduces NLRP3 priming
induced by Alu RNA. Indeed, as provided in the bar graph of
FIG. 13, Alu RNA transfection increases NLRP3 mRNA
levels in primary human RPE cells at 16 hours, an event
termed "priming" (Y-axis) compared to mock (transfection
reagent alone). This effect is blunted by co-administration of
d4 T (1 00 uM) and normalized to ISS RNA control.
Furthermore, in exemplary embodiments of the present
disclosure, d4T reduces IL-l beta priming induced by Alu
RNA. FIG. 14 illustrates thatA!u RNA transfection increases
IL-l beta mRNA levels in primary human RPE cells at 24
hours, an event termed "priming", (Y-axis) compared to mock
(transfection reagent alone). This effect is blunted by coadministration of d4T (100 uM) and normalized to ISS RNA
control.
Meanwhile, in some embodiments, d4T reduces mitochondrial ROS caused by Alu expression. FIG. 15 demonstrates
that enforced expression of Alu (pA!uA) causes increased
mitochondrial reactive oxygen species (mtROS), as detected
by MitoSox assay. In order to produce FIG. 15, primary
human RPE cells were incubated with Alu expressing plasmid or control plasmid(pUC19)withorwithout d4T.After 15
hours cells were co-stained for mtROS (red) and for cell
count, nuclei (blue; Hoechst DNA stain). Cells in the pA!uA
group exhibited greater mtROS staining (red) compared to
pUC19 control, an effect that is reduced in pAluA+d4T
treated cells.
And in further embodiments, d4T does not inhibit ATP
release induced by Alu RNA. (FIG. 16) Primary human RPE
cells treated with Alu RNA for the times indicated release
ATP. To provide FIG. 16, cell culture supernatant was collected from mock or Alu RNA treated cells, with or without
d4T. ATP was detected using an ATP-dependent luciferase
assay. And, notably, d4T did not affect ATP release.
In certain embodiments, d4T reduces ATP-induced cell
permeability to Yo-Pro! (P2X7 receptor assay), as shown in
FIG. 17. To prepare FIG. 17, THP-1 cells differentiated into
macrophages by PMA allowed entry of the large fluorescent
dye Yo-Pro 1, in an assay for P2X7 receptor activity. It was
observed that d4T dose-dependently reduced Yo-Pro entry
induced by ATP, determined by an area -scan fluorescent measurement in a 96 well microplate reader. Indeed, FIG. 17
provides the results of the fluorescence measurement in relative fluorescence units (RFU, y-axis ).

Furthermore, it has been shown that d4T reduces extracellular potassium levels that increase after Alu RNA transfection. (FIG. 18) Indeed, cell culture potassium levels increase
in primary human RPE cells treated with Alu RNA for 6
hours, an effect that is reduced by d4T co-administration. For
FIG. 18, potassium levels were determined in cell culture
supernatants spectrophotometrically using a potassium-dependent pyruvate kinase assay.
Next, in some embodiments, d4T blocks bzATP-induced
cell permeability to Yo-Pro! (P2X7 receptor assay), as shown
in FIG. 19. d4T blocked YO-PRO-I iodide entry in HEK293
cells stably expressing the human P2X7 receptor stimulated
with the P2X7 -selective agonist bzATP. Cells were pre-incubated with d4T for 30 minutes prior to addition of bzATP/
YO-PRO, and fluorescence at 4S5/515 nm measured at t=30
minutes.
Moreover, d4T blocks Alu-induced RPE degeneration and
Caspase-1 activation independent of reverse transcriptase
inhibition.
In some embodiments, the present disclosure is directed to
a compound having the structure(s) provided in FIG. 20. FIG.
20 includes a chemical structure of methoxy-d4 T (me-d4 T)
and of d4T. As shown in FIG. 20, a single substitution of the
ribose 5' hydroxyl group with a methoxy group (circled) has
been designed by the inventors of the present disclosure to
prevent d4T phosphorylation. Accordingly, in some embodiments, the present disclosure is directed to a compound comprising a single substitution of a ribose 5' hydroxyl group with
a methoxy group. And, in some embodiments, the present
disclosure provides compounds comprising a methoxy group
in place of a ribose 5' hydroxyl group for preventing phosphorylation, such as d4T phosphorylation.
The present disclosure further provides the results of additiona! experiments in FIG. 21-FIG. 23. Indeed, FIG. 21 is a
Western blot ofCaspase-1 activation (p20 subunit) in primary
human RPE cells transfected with Alu RNA±me-d4T; FIG.
22 shows cells, wherein unmodified d4T, but not me-d4T,
blocks replication of a GFP-expressing lentivirus in HeLa
cells; and FIG. 23 provides a graph illustrating that unmodified d4T, but not me-d4T, reduces mtDNA levels (normalized
to chromosomal DNA exon-intron junction sequence) in primary mouse RPE cells as determined by real-time quantitative PCR. n=4, *p<0.05 by Student's t-test.
In some embodiments, it has been shown that Me-d4T
(intraperitoneal injection) prevents Alu-induced RPE degeneration in mice. FIG. 24, top row, provides flat mounts stained
for zonula occludens-1 (Z0-1; red), bottom row. Degeneration is outlined if FIG. 24 by blue arrowheads. Representative
images of n=4 are shown.
Meanwhile, FIG. 25 provides a schematic overview of
me-d4T synthesis, and FIG. 26 is an HPLC chromatogram of
me-d4T (peak #6) final product, >97% purity. And FIG. 27 is
a lH NMR spectroscopy of me-d4T final product, wherein
the chemical shifts are consistent with the structure, and FIG.
28 provides the results ofliquid chromatography/mass spectrometry of me-d4T final product, m/z ratio consistent with
the structure.
FIG. 29, FIG. 30 and FIG. 31 provide for methoxy variants
of nucleoside analogs. Specifically, FIG. 29 shows the chemical structure of3TC (2'3' dideoxycytidine ); FIG. 30 provides
the chemical structure of AZT (3'-azido-2',3'-dideoxythymidine); and FIG. 31 shows the chemical structure of ABC
(cyclopropylaminopurinylcyclopentene). In each of FIGS.
29-31, the methoxy variation (0-methyl group) of nucleoside
analog is circled. Further, FIG. 32 shows a cell permeant
variant of d4T (IC-d4T), where "n" group is equal to 11.
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Derivatives include cell permeant variants of 3TC, AZT,
ABC, where the nucleobase group (circled) may be replaced,
in various embodiments, by 3TC, AZT, ABC, or methoxyvariants ofd4T, 3TC,AZT,ABC (FIG. 29-31), or derivatives
thereof.
Meanwhile, FIG. 33 provides the chemical structure of an
exemplary NRTI according to the present disclosure.
In certain embodiments, the present disclosure provides
that NRTis block Alu-induced RPE degeneration and/or
Caspase-1 activation. For example, FIG. 34 shows a Western
blot ofCaspase-1 activation (p20 subunit) and IRAK4 phosphorylation in primary human RPE cells transfected withA!u
RNA±d4T. FIG. 35 is a Western blot ofCaspase-1 activation
in human RPE cells transfected withA!u RNA±NRTis (3TC,
AZT, ABC). FIG. 36 shows that pA!u causes RPE degeneration, which is prevented by oral administration of d4T, and
FIG. 37 shows that pA!u causes RPE degeneration, which is
prevented by intraperitoneal administration of AZT. FIG. 36
and FIG. 37 include fundus photographs: top row; flat mounts
stained for zonula occludens-1 (Z0-1; red), bottom row.
Degeneration is outlined by blue arrowheads. Scale bars, 50

FIGS. 51-54 show that, in some exemplary embodiments,
P2X7-dependent pore function mediates Alu-induced
Caspase-1 activation. Indeed, FIG. 51 is a Western blot of
Caspase-1 activation (p20 subunit) in primary human RPE
cells transfected withA!u RNA, with short peptide (Panxl 10),
which blocks P2X7 pore function but not cation flux (vs.
scrambled peptide: Scr Panxl 10); FIG. 52 is a Western blot of
Caspase-1 activation (p20 subunit) in primary human RPE
cells transfected withA!u RNA, with calmidazolium (FIG. 32
provides the chemical structure of IC- and EC-d4T used),
which blocks P2X7 cation flux but not pore function; and
FIG. 53 is a Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected withA!u RNA,
with cell permeable (I C), cell-impermeable (EC), or unmodified (no tag) d4T. Furthermore, FIG. 54 shows that d4T prevents pAin-induced mitochondrial ROS generation in primary human RPE cells. In FIG. 54, mitochondrial reactive
oxygen species (ROS) were visualized with MitoSox (Red)
and cell nuclei with Hoechst (Blue).
One of ordinary skill in the art will recognize that additional embodiments or implementations are possible without
departing from the teachings of the present disclosure or the
scope of the claims which follow. This detailed description,
and particularly the specific details of the exemplary embodiments and implementations disclosed herein, is given primarily for clarity of understanding, and no unnecessary limitations are to be understood therefrom, for modifications will
become obvious to those skilled in the art upon reading this
disclosure and may be made without departing from the spirit
or scope of the claimed invention.
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FIGS. 38-41 illustrate that NRTis block LPS/ATP-induced
inflammasome activation. FIGS. 38 and 39 show that d4T
blocked Caspase-1 (FIG. 38) and IL-l beta (FIG. 39) activation in LPS/ATP treated primary mouse bone marrow -derived
macrophages as determined by western blot of cell culture
media and lysate. Moreover, FIG. 40 presents chromatograms
showing that Raji TK+ cells, but not Raji TK- cells, phosphorylate AZT to AZT-triphosphate (AZT-TP) as determined by
liquid chromatography-mass spectrometry (LC-MS). And
FIG. 41 shows that AZT blocks IL-l beta activation by LPS/
ATP in both Raji TK- and TK+ cells as determined by western
blot of celllysates. Representative images of n=3-4 experiments are provided in each of FIGS. 38-41.
In some embodiments, the present disclosure provides that
NRTis selectively block P2X7 pore function and P2X7driven models of graft rejection and sterile liver inflammation, as shown in FIGS. 42-43. FIG. 42 is a bar graph illustrating that d4T does not blockA!u-inducedATP release from
primary human RPE cells (n=4). Meanwhile, FIG. 43 is a
graph illustration showing that NRTis selectively block P2X7
pore function and P2X7-driven models of graft rejection and
sterile liver inflarmnation, providing a graph of the fluorescence(% ofbzATP) over time (minutes).
And in certain exemplary embodiments, the present disclosure provides that d4T blocks Caspase-1 activation without reducing Alu RNA levels. Accordingly, FIG. 44 provides
a
Western blot of Caspase-1 activation (p20 subunit) and
IRAK4 phosphorylation in primary mouse RPE cells transfected withA!u RNA±d4T.And FIG. 45 presents a Northern
blot of biotin-UTP-labeled Alu RNA-transfected primary
humanRPE cells. Notably, in FIG. 45, d4T didnotreduceA!u
RNA levels (normalized to u6 RNA).
Next, FIGS. 46-47 provide LC-MS/MS spectra of AZTtriphosphate (AZT-TP, target compound; FIG. 46) andAZUtriphosphate (AZU-TP, internal standard; FIG. 47). And
FIGS. 48-49 show the chromatographic separation of Raji
TK- cells spiked withAZT-TP (FIG. 48) andAZU-TP (FIG.
49) with MS spectra (insets) to confirm identity of designated
peaks.
FIG. 50 is a standard curve of AZT-TP standards (black
circle). Raji TK+ samples treated with AZT produced AZTTP (white triangles), whereas AZT-TP was not detectable in
Raji TK- cells treated withAZT. FIG. 50 is representative of
two experiments.
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or a pharmaceutically acceptable salt thereof;
(iii) stavudine (d4T);
(iv) lamivudine (3TC);
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Activation of the native 45-kDa precursor form of interleu(vi) azidothymidine (AZT);
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(vii) abacavir (ABC); and
(viii) a combination thereof.
INCORPORATION BY REFERENCE
2. The method of claim 1, comprising inhibiting inflammasome activation by Alu RNA associated with a cell.
All publications, patents, and patent applications men- 30
3. The method of claim 2, wherein the cell is a retinal
tioned in this specification are herein incorporated by referpigmented epithelium cell, a retinal photoreceptor cell, a
ence to the same extent as if each individual publication,
choroidal cell, or a combination thereof.
patent, or patent application was specifically and individually
4. The method of claim 1, comprising reducing ATP-inindicated to be incorporated by reference.
35 duced permeability of a cell.
It will be understood that various details of the presently
s. The method of claim 4, wherein the cell is a retinal
disclosed subject matter can be changed without departing
pigmented epithelium cell, a retinal photoreceptor cell, a
from the scope of the subject matter disclosed herein. Furchoroidal cell, or a combination thereof.
thermore, the foregoing description is for the purpose of
illustration only, and not for the purpose oflimitation.
6. The method of claim 1, comprising reducing an amount
40
of mitochondrial reactive oxygen species in a cell.
20

7. The method of claim 1, comprising inhibiting activation
of at least one inflammasome in a subject's eye.

What is claimed is:
1. A method for treating retinal degeneration, comprising:

administering an effective amount of a composition to a
subject in need of treatment for retinal degeneration,

45

wherein the composition comprises a reverse transcriptase
inhibitor selected from:
(i) a compound having the structure of

8. The method of claim 7, wherein the at least one inflammasome is selected from an NLRP3 inflammasome, an IL-l
beta inflammasome, and a combination thereof.
9. The method of claim 1, wherein the composition comprises a pharmaceutically acceptable carrier.
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10. A compound having the structure
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or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt thereof.
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11. A pharmaceutical composition comprising the com-

(ii) a compound having the structure of

pound of claim 10 and a pharmaceutically acceptable carrier.
12. A compound having the structure
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or a pharmaceutically acceptable salt thereof.
15. The method of claim 14, wherein the composition
further comprises: stavudine (d4T), lamivudine (3TC),
cordycepin, azidothymidine (AZT), abacavir (ABC), or a
combination thereof.
16. The method of claim 14, comprising inhibiting inflam25
masome activation by Alu RNA associated with a cell.
17. The method of claim 16, wherein the cell is a retinal
pigmented epithelium cell, a retinal photoreceptor cell, a
choroidal cell, or a combination thereof.
30
18. The method of claim 14, comprising reducing ATPinduced permeability of a cell.
19. The method of claim 18, wherein the cell is a retinal
pigmented epithelium cell, a retinal photoreceptor cell, a
choroidal cell, or a combination thereof.
35
20. The method of claim 14, comprising reducing an
amount of mitochondrial reactive oxygen species in a cell.
21. The method of claim 14, comprising inhibiting activation of at least one inflmasome in a subject's eye.
22. The method of claim 21, wherein the at least one
40
inflammasome is selected from an NLRP3 inflmasome, an
IL-l beta inflammasome, and a combination thereof.
23. The method of claim 14, wherein the composition
comprises a pharmaceutically acceptable carrier.
20

or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising the compound of claim 12 and a pharmaceutically acceptable carrier.
14.Amethod for treating retinal degeneration, comprising:
administering an effective amount of a composition to a
subject in need of treatment for retinal degeneration,
wherein the composition comprises:
(i) a compound having the structure of

or a pharmaceutically acceptable salt thereof; or
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